Global Terbium-155 Market Strategic Research Report

Scope of the Report

In 2025, global production of Terbium-155 was approximately 62 grams, with an average global market price of around $42,000 per gram. That year, total global production capacity for Terbium-155 reached 110 grams, and the industry's average gross profit margin stood at 27%. Terbium-155 (Tb-155) is an artificial radioisotope of the rare-earth element terbium, characterized by an atomic number of 65 and a mass number of 155. It has a half-life of approximately 5.32 days and decays primarily via electron capture into stable gadolinium-155 (Gd-155). Its decay releases gamma rays—notably at energies of approximately 87 keV and 105 keV—that are suitable for Single-Photon Emission Computed Tomography (SPECT); it also produces Auger electrons and internal conversion electrons. Consequently, Tb-155 serves not only as a diagnostic imaging radionuclide but also holds potential for research into localized electron therapy. Its relatively long half-life allows for the monitoring of the in vivo distribution of antibodies, peptides, and other slow-clearing radiopharmaceuticals over several days. Furthermore, it can form a "theranostic pair" with the therapeutic isotope Terbium-161 (Tb-161)—sharing identical elemental chemistry—thereby minimizing discrepancies in chemical properties and pharmacokinetics between the diagnostic and therapeutic radionuclides.

The upstream segment of the Tb-155 industry chain primarily encompasses enriched Gd-155 or Gd-156 targets, low-to-medium energy cyclotrons, high-energy proton accelerators, on-line or off-line mass separation equipment, target stations, hot cells, and radiochemical separation consumables. CERN-MEDICIS obtained its first batch of Tb-155 in 2017, demonstrating that large-scale isotope separation facilities can supply high-purity, non-conventional medical radionuclides. Key upstream barriers include the cost and recovery of enriched gadolinium targets, the beam-resistance of the target layer, the control of radioactive impurities, and the capability for stable, batch-wise production. The midstream segment consists mainly of national laboratories, medical isotope centers, radiopharmacies, and radiopharmaceutical R&D institutions; these entities are responsible for separating Tb-155 from irradiated gadolinium targets, recovering the expensive enriched gadolinium target material, and converting the Tb-155 into a trivalent terbium ion solution suitable for radiolabeling. As terbium and gadolinium are both lanthanides with similar chemical properties, their separation typically requires techniques such as cation exchange, extraction chromatography, ion chromatography, or multi-column purification to yield products with high radionuclidic purity and high specific activity. Subsequently, Terbium-155 can be conjugated with peptides, small molecules, or antibodies using chelators like DOTA to produce investigational radiopharmaceuticals such as Terbium-155-DOTATOC. Key mid-stream quality control parameters include radionuclide identity, radionuclidic purity, radiochemical purity, specific activity, metal impurities, pH, sterility, endotoxin levels, and labeling stability. Studies have successfully produced high-quality Terbium-155 (at the ~200 MBq level) using cyclotrons and validated it through cellular uptake and animal SPECT/CT imaging, demonstrating that the production process has reached the level required for preclinical research. The downstream sector of the industry chain primarily comprises nuclear medicine centers, oncology hospitals, radiopharmaceutical companies, preclinical research institutions, and precision medicine laboratories. The primary application of Terbium-155 is SPECT imaging, which enables the monitoring of the long-term distribution of receptor-targeting drugs, antibodies, and peptides in tumors and normal organs, as well as facilitating patient screening, pharmacokinetic analysis, and therapeutic dosimetry assessment. Since Terbium-155 and Terbium-161 share identical elemental chemical properties, the same chelators and targeting molecules can be used to construct a true "same-element" theranostic pair (Terbium-155 for diagnosis and Terbium-161 for therapy); furthermore, the set comprising Terbium-149, Terbium-152, Terbium-155, and Terbium-161 covers alpha therapy, PET, SPECT, and beta/Auger electron therapy, respectively, representing a suite of terbium radionuclides with platform-level potential. The Auger electrons emitted by Terbium-155 also make it valuable for research into localized cell killing, although its potential development into a therapeutic product depends on the efficiency with which the radionuclide enters the cell and the cell nucleus. Currently, downstream activities remain focused primarily on animal imaging, quantitative SPECT, radiopharmaceutical paired evaluation, and production technology validation; the main constraints on large-scale clinical application are insufficient stable supply, the high cost of enriched target materials, and the fact that impurity control and GMP production systems have not yet fully matured.

Terbium-155 decays primarily through electron capture (EC), emitting moderately energetic X-rays and gamma photons (approximately 105 keV). This energy is ideal for SPECT imaging (single-photon emission computed tomography), enabling the acquisition of clear, high-resolution images. Furthermore, it emits virtually no high-energy beta particles, minimizing damage to surrounding healthy tissue.

Terbium has a significant advantage in that it is available in several other radioisotopes, including terbium-155 (α-emitter, used in therapy), terbium-155 (β-emitter, used in PET imaging), and terbium-155 (β-emitter, used in therapy). This means that the same element (terbium) can be used to label the same targeting molecule (such as an antibody or peptide), enabling seamless transition between diagnosis and therapy. For example, terbium-155 can be used for diagnostic imaging to determine lesion location and drug distribution, and then terbium-155 or terbium-155 can be used for precisely targeted therapy. This is known as "integrated diagnosis and therapy." Terbium-155, due to its excellent radionuclide properties and potential as a key component of integrated diagnosis and treatment, has become a hot topic in the research and development of new medical radioisotopes. Currently, its development focuses primarily on optimizing accelerator production technology and developing automated separation and purification processes. While facing challenges such as high costs and a fragile supply chain, with technological advancements and the growing global demand for precision medicine, terbium is expected to play a more significant role in nuclear medicine in the future.

This report presents a comprehensive overview of the global Terbium-155 market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Radionuclide Purity: <99%
• Radionuclide Purity: ≥99%

Segment by Product Form

• Terbium-155 Radionuclide Stock Solution
• Terbium-155 Labeling Intermediate
• Terbium-155 Irradiation Target

Segment by Production Route

• Proton-induced Reaction on Enriched Gadolinium-155 Target
• Proton-induced Reaction on Enriched Gadolinium-156 Target
• Proton-induced Reaction on Natural Gadolinium Target
• Deuteron-induced Reaction on Gadolinium Target

Segment by Quality Grade

• Nuclear Physics Research Grade
• Medical Isotope Research Grade
• Metrological Standard Grade

Segment by Application

• Diagnostic Imaging
• Therapeutic Applications
• Scientific Research

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Terbium-155 market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Diagnostic Imaging, Therapeutic Applications, Scientific Research evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact